Drug
177Lu-octreotide, DOTA(0)-Tyr(3)- clinical trials
Keep track of what changes. Save the 177Lu-octreotide, DOTA(0)-Tyr(3)- studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2023 (3)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2023 | 3 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 5
ITM Solucin GmbH (2) · Grupo Espanol de Tumores Neuroendocrinos (1) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1) · University of Warmia and Mazury (1) · Excel Diagnostics and Nuclear Oncology Center (1) · British Columbia Cancer Agency (1)
Related medicines
As reviewed, each with the page that says it.
- One of Radiopharmaceuticals source
Studies
Open first, then newest update. How each study uses 177Lu-octreotide, DOTA(0)-Tyr(3)- is read from its arms, and is right about nine times in ten.
Testing it · 7
- Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive TumorsRecruitingPhase 1ITM Solucin GmbHNCT06441331Written as Lutetium Lu 177-Edotreotide
- Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.RecruitingPhase 3Grupo Espanol de Tumores NeuroendocrinosNCT05918302Written as 177Lu-edotreotide
- "Receptor Radionuclide Therapy With 177Lu-DOTATOCRecruitingPhase 2Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSNCT06045260Written as 177Lu-DOTATOC
- Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET PatientsActive, not recruitingPhase 3ITM Solucin GmbHNCT03049189Written as 177Lu-edotreotide PRRT
- Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.WithdrawnPhase 2Excel Diagnostics and Nuclear Oncology CenterNCT04276597Written as 177Lu-DOTATOC
- 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETsWithdrawnPhase 2British Columbia Cancer AgencyNCT04915144Written as 177Lu-DOTATOC
- Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine CancerStatus unknownPhase 2University of Warmia and MazuryNCT04194125Written as 177Lu-DOTATOC
Given in every arm · 2 — 177Lu-octreotide, DOTA(0)-Tyr(3)- is usual care beside what is tested
- Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.RecruitingPhase 3Lund University HospitalNCT05387603Written as 177Lu-DOTATOC
- Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)RecruitingEarly Phase 1University Hospital, Basel, SwitzerlandNCT05359146Written as 177Lu-DOTATOC